Loss-of-function pathogenic variants in BRCA1 confer a predisposition to breast and ovarian cancer. Genetic testing for sequence changes in BRCA1 frequently reveals a missense variant for which the impact on cancer risk and on the molecular function of BRCA1 is unknown. Functional BRCA1 is required for the homology-directed repair (HDR) of double-strand DNA breaks, a critical activity for maintaining genome integrity and tumor suppression. Here, we describe a multiplex HDR reporter assay for concurrently measuring the effects of hundreds of variants of BRCA1 for their role in DNA repair. Using this assay, we characterized the effects of 1,056 amino acid substitutions in the first 192 residues of BRCA1. Benchmarking these results against variants with known effects on DNA repair function or on cancer predisposition, we demonstrate accurate discrimination of loss-of-function versus benign missense variants. We anticipate that this assay can be used to functionally characterize BRCA1 missense variants at scale, even before the variants are observed in results from genetic testing.
Introduction
Genetic testing for genes associated with hereditary breast and ovarian cancer often reveals a BRCA1 missense variant whose impact on the molecular function of the encoded protein, and therefore its contribution to cancer risk, is unknown. Such variants are reported as variants of uncertain significance (VUSs). VUSs cause distress for both physicians and individuals with a family history of cancer and can lead to unnecessary surgeries. 1, 2 As genetic testing becomes more common in the clinic, reports of missense VUSs are rapidly accumulating in public databases. 3 Additional VUSs arise from the increasingly widespread sequencing of tumor genomes and exomes to guide precision therapy. For rare missense variants, clinically calibrated functional assays are particularly helpful for aiding classification.
The most commonly reported class of VUSs in BRCA1 is single-nucleotide variants (SNVs), which are predicted to result in missense amino acid substitutions. As of May 2018, 1,794 missense VUSs in BRCA1 are in the clinical genetics database ClinVar. 3 An additional 231 missense variants have conflicting interpretation reports, suggesting that clinical testing labs apply discordant classification criteria. Across BRCA1's 1,863 amino acids, 12,458 SNVs are predicted to result in a missense substitution that might or might not affect protein function; these are often considered VUSs when identified as either a germline or somatic variant in an individual. Most strategies for variant interpretation fail when missense variants are novel or rare because clinical information for correlation is correspondingly scarce. [4] [5] [6] [7] Computational variant-effect prediction algorithms scale without limit, but these are not accurate enough for routine clinical use and furthermore contribute to discordance. 8, 9 Functional assays, on the other hand, are considered by the American College of Medical Genetics (ACMG) guidelines as strong evidence for or against the pathogenicity of missense variants. 8 However, performing a post hoc functional assay for each BRCA1 SNV as it is discovered is infeasible at their current rate of accumulation. BRCA1 is required for the maintenance of genome integrity via the homology-directed repair (HDR) pathway. The effect of variants in BRCA1 on its HDR function can be determined in tissue culture with a GFP-based reporter assay for intact DNA repair function. 10 For BRCA1 variants tested thus far, this assay has stratified the protein function of known benign and pathogenic variants with high sensitivity and specificity. [11] [12] [13] [14] Here, we have developed a multiplex version of this HDR assay with the goal of testing all possible protein variants in the BRCA1 N terminus (residues , which includes the RING domain (residues 7-98). Proper folding of the RING domain is required for the stability and function of the full-length protein. 12, 15, 16 In addition, all missense substitutions that are known to cause increased cancer risk map to either the RING or BRCT domain.
Using the HDR reporter cell line with integrated BRCA1 variant libraries, we tested approximately 600 BRCA1 missense variants per experiment. Loss-of-function missense variants were identified by their relative depletion from the subset of GFP þ cells. BRCA1's first 98 amino acids, which encode the RING domain, were considerably more sensitive to missense substitutions than the subsequent 94 residues. The results of the multiplex assay correlate well with the results from singleton HDR reporter assays and other functional assays. Furthermore, known pathogenic variants can be separated from known benign variants by their recurrent depletion from the functional population in replicate experiments. Our results for 63 VUSs or variants with conflicting reports of pathogenicity from ClinVar show that five are nonfunctional for HDR, whereas 57 are functional. We suggest improvements to our current protocol to potentially increase its throughput and accuracy. Finally, we anticipate that this assay can be used to functionally characterize BRCA1 missense variants at scale in order to provide the additional information necessary for more definitive interpretation of VUSs in the clinic.
Material and Methods
All enzymes were purchased from New England BioLabs unless stated otherwise. Primer sequences can be found in Table S1 .
Creating the HeLa-DR-FRT Cell Line
A description of the HeLa-DR (direct repeat) cell line can be found in the report by Ransburgh et al. 12 To create a FLP-in version of
HeLa-DR, we stably integrated a flippase recognition target (FRT) sequence into the cells by using the pFRT/lacZeo plasmid (Thermo Fisher Scientific). We tested Zeocin-resistant clones that had a single integration site detected by Southern blot for high-activity integration sites by using the mammalian b-galactosidase activity assay (Gal-Screen, Thermo Fisher Scientific). Clonal expansion of the selected colony established the HeLa-DR-FRT cell line.
Site-Saturation Mutagenesis Libraries and Barcoding
The hemagglutinin (HA)-tagged BRCA1 N-terminal HindIII-EcoRI fragment containing amino acids 1-302 was cloned into the pUC18 plasmid. Two site-saturation mutagenesis libraries of BRCA1 were constructed by a previously reported inverse-PCRbased method. 17 Pool 1 included substitutions in amino acids 2-96, and pool 2 included 97-192. For each codon, 30 base mutagenic primers were ordered with machine-mixed NNK bases at the 5 0 end of the sense oligonucleotide (N ¼ ACTG; K ¼ GT).
The mutagenized HA-BRCA1 2-302 fragments were ligated into the EcoRI and HindIII sites of the BRCA1 cDNA in the pcDNA5/FRT-TO vector that had been modified to lack a second EcoRI site in the gene for hygromycin resistance and include a second multiple cloning site at the MluI and NruI sites for the barcode. A 16 base degenerate barcode encoded on oligonucleotides (pc5_barcode_longer_ W and _C) that had been annealed, extended, and digested with NotI and SbfI was then ligated into the second multiple cloning site. Assessment of colonyforming units after barcode ligation and transformation detected $25,000 barcoded clones for each of the pool 1 and pool 2 libraries. Metrics for the variant library cloning steps can be found in Table S4 .
Assigning Barcodes to Variants by Using PacBio Long Reads
To prepare the circular SMRTbell templates for the pool 1 and 2 variable regions and barcode, we removed the intervening sequence between the barcode and the BRCA1 N-terminal variable region by using NotI and HindIII restriction digest followed by end repair and blunt-end ligation. 18 The ligations were transformed into E. coli to remove concatamers. We then cut the plasmids with SbfI and EcoRI to release the barcode and BRCA1 N-terminal variable region. Custom SMRTbell adapters pb_SbfI and pb_EcoRI were sticky-end ligated to the purified fragment. To make a working stock of 20 mM SMRTbell adaptors in 10 mM Tris, 0.1 mM EDTA, and 100 mM NaCl, we heated them to 85 C and snap cooled them on ice. The ligation reaction contained 0.3 pmol of purified fragment, 0.4 mM of each adaptor, 0.25 mL of EcoRI-HF, 0.25 mL of SbfI-HF, 13 ligase buffer, and 0. 
Integration of Libraries into Cells
For each of the BRCA1 plasmid libraries (pools 1 and 2), 70-80 million HeLa-DR-FRT cells in ten 10 cm tissue-culture plates were transfected with 200 mg of pOG44 to express a modified flippase enzyme and 100 mg of the pcDNA5/FRT BRCA1 variant library. Plasmids were diluted in 10 mL of Opti-MEM and incubated for 5 min. 300 mL of Lipofectamine 2000 (Thermo Fisher Scientific) was diluted in 10 mL of Opti-MEM for 5 min. The Lipofectamine and plasmid dilutions were then combined and incubated for 20 min. The mixture was then applied directly to cells. After 24 hr, cells were trypsinized and transferred to ten 15 cm tissue-culture dishes. Because pOG44 flippase has reduced activity at 37 C, 4-8 hr after transfer, the cells were moved from a 37 C humidified incubator to a 30 C humidified incubator for 24 hr. The cells were then returned to 37 C for an additional 24 hr. Approximately 72 hr after the initial transfection, the cells were trypsinized and transferred to 20 15 cm plates containing selection media (50% fresh DMEM supplemented with 10% fetal bovine serum, 50% filter-sterilized conditioned media, and 550 mg/mL hygromycin B). Hygromycin-resistant cells were selected at 37 C for 24 hr. The cells were washed with sterile phosphate-buffered saline (PBS), and the selection media were replaced after the first 24 hr and again every 48 hr until cell colonies were visible without a microscope (about 14 days). Colonies were then counted, trypsinized, resuspended in 20 mL of culture media, and mixed thoroughly (colony counts can be found in Table S4 ). 15 mL of the resuspended cells was frozen in 1 mL aliquots. 5 mL of the resuspended colony mixture was plated onto three 15 cm plates (3, 1.5, and 0.5 mL) and incubated for 24 hr. The plate that was closest to a confluent monolayer of cells was passaged. We passaged the cells for an additional 2 weeks before performing HDR reporter experiments to assure loss of the unintegrated BRCA1 expression plasmid.
HDR Reporter Assays, Sorting, and gDNA Prep
HDR reporter assays and fluorescence-activated cell sorting (FACS) were performed for each of the BRCA1 variant libraries in quadruplicate. A confluent 10 cm plate of the HeLa BRCA1 variant cell line was trypsinized and resuspended in 10 mL of culture media. 65 mL of the suspension was plated in each of 48 wells across two 24-well tissue-culture plates. 24 hr later, each well was transfected with 30 pmol of small interfering RNA (siRNA) and 1.5 mL of Oligofectamine (Thermo Fisher Scientific). Oligofectamine was diluted with 6 mL of Opti-MEM, and siRNA was diluted with 25 mL of Opti-MEM for 5 min. The dilutions were then combined and incubated for an additional 30 min. The transfection mixture was then applied directly to the cells. 24 hr later, the cells were trypsinized and transferred to four 6-well tissue culture plates and then incubated for another 24 hr. Each well was then transfected with 50 pmol of siRNA, 3 mg of pCBASceI (for I-SceI expression), and 3 mL of Lipofectamine 2000. Plasmid and siRNA were diluted in 125 mL of Opti-MEM, and Lipofectamine was diluted in 125 mL of Opti-MEM and then incubated for 5 min. The dilutions were combined and incubated for an additional 20 min. The transfection mixture was then applied directly to cells. 4-6 hr later, the culture media were replaced with fresh media. siRNA of the BRCA1 3 0 UTR, BRCA1 coding sequence, and control were used in both rounds of transfection. After 24 hr, we analyzed one well of cells treated with each condition for GFP expression by using flow cytometry to confirm transfection efficiency. If cells treated with control siRNA and 3 0 UTR siRNA fell within 7%-9%
and 4%-7% GFP þ cells, respectively, and cells treated with siRNA of the BRCA1 coding sequence were 1%-2% GFP þ , the experiment would proceed. 72 hr after transfection, the cells were pooled according to treatment and sorted by FACS with an Aria IIu instrument. Cells were resuspended and pooled in filter-sterilized sorting buffer containing 13 PBS (Ca 2þ -and Mg 2þ -free), 5 mM EDTA, 25 mM HEPES (pH 7.0), and 1% heat-inactivated fetal bovine serum dialyzed against Ca 2þ and Mg 2þ PBS. A minimum of 500,000 GFP þ cells and a maximum of two million GFP À cells were collected per pool (Table S5) 
Barcode Amplification and Sequencing
To amplify the barcode from gDNA, we spread the GFP þ and GFP À populations over 8-16 reactions each containing 250 mg of gDNA (220,000-440,000 genome equivalents by weight given $9 pg per triploid HeLa genome; see Table S5 ). Reactions also contained Kapa2G Robust Polymerase (Kapa Biosystems), a primer that annealed to the SV40 promoter 5 0 to the integrated plasmid and a primer adjacent to the barcode (SV40_F and newpc5bc_nexteraR). Table S5 ). For the pilot 16-plex experiment without barcodes, the BRCA1 region containing the variants was amplified and directly sequenced.
Variant Scoring, Classifications, and Depletion Score FASTQ files containing barcodes for each sample and the barcode map for each library were used as input for the software package Enrich2. 20 Enrich2 was used to count the barcodes, associate each barcode with a nucleotide variant, and then translate and count both the unique nucleotide and unique amino acid variants. Barcodes assigned to variants containing insertions or deletions were removed from analysis. We converted the counts for each protein variant to frequencies by dividing them by the total number of variant counts for each sample. The ratio of the frequency of each variant in the GFP þ population over its frequency in the GFP À population was calculated. That ratio for each variant was then normalized to the GFP þ /GFP À ratio for the wild-type
Counts and scores for each variant can be found in Table S6 . Variants with multiple amino acid substitutions were removed from further analysis.
To construct the binary functional/nonfunctional classifier for variants, we first determined that the standard deviation of the score decays according to read count in a way that can be modeled by a log 10 -log 10 curve. We then modeled the decay of the standard deviation of scores from the control siRNA experiment. Next, we applied that model to the standard deviation of scores from the BRCA1 siRNA experiment and calculated a p value and a false-discovery-rate-adjusted q value for each variant to determine whether it was similar to or significantly different from that of the control siRNA experiment (q < 0.055). Finally, we determined where the false positives in the control experiments occurred along the continuum of read counts to assign a read-count threshold for the BRCA1 siRNA condition. A read-count threshold is usually part of the heuristic applied to remove noise due to stochastic dropout from deep mutational scanning data. 16 We removed variants with a read count below that threshold from further analyses. These analyses were performed with R studio; an R markdown file containing all data manipulations is supplied as Data S1.
The depletion score represents the number of replicates in which a variant was found to be depleted from the BRCA1 siRNA GFP þ population. Only variants that were present above the readcount threshold in at least three replicates had depletion scores. Depletion scores for those 1,056 variants can be found in Table S7 .
Results

A Multiplex Assay for Measuring the Effect of Protein Variants on HDR
The multiplex HDR reporter assay described here is based on an assay developed by the Jasin laboratory. 10 In the reporter assay for single variants of BRCA1, a cell line has two inactive GFP-encoding alleles integrated into its genome. A site-specific double-strand DNA break is induced in one of the inactive GFP alleles by transfection of a plasmid for the expression of the I-SceI endonuclease, and if this break is repaired via homologous recombination with the second inactive GFP allele as the template, then the GFP sequence is corrected, resulting in conversion of a GFP À cell into a GFP þ cell ( Figure 1A ). Loss of BRCA1 activity (e.g., by depletion with siRNA) results in cells that cannot repair the DNA break by HDR, and such cells remain GFP À . We previously used this assay [11] [12] [13] [14] to test the competence of 158 individual BRCA1 missense variants to rescue the loss of endogenous BRCA1. BRCA1 HDR function with these individual assays demonstrates 100% specificity and 93% sensitivity for predicting the cancer risk associated with variants with established interpretations (n ¼ 48; Figure S1 and Table S2 ). The one known pathogenic variant misidentified as benign, c.330A>G (p.Arg71Gly), affects splicing rather than protein function 21 and therefore could not have been classified correctly with an assay that expresses variants within a cDNA copy of BRCA1 (MIM: 113705). Given this functional assay's established specificity and sensitivity for predicting clinical pathogenicity, we sought to convert it to a multiplex format in order to generate high-confidence predictions for hundreds of BRCA1 variants within a single experiment.
As a pilot version of a multiplex HDR reporter assay ( Figure 1B and Table S3 ), we prepared a pool of plasmids containing the WT BRCA1 and 15 BRCA1 variants that had been tested individually ( Figure 1C) . We integrated these plasmids en masse into the HeLa-derived HDR reporter cell line, which we had engineered to contain a single recombinase-based landing pad (HeLa-DR-FRT; Material and Methods). Although it has low efficiency, we used a recombinase-based system to ensure that only a single variant would be integrated into a common site in each cell, thus ensuring consistent expression levels and avoiding complications associated with lentiviruses, e.g., variable integration sites and template switching. 22 After selecting for cells containing an integrated BRCA1 variant, we performed the three steps of the HDR reporter assay. First, we depleted endogenous BRCA1 with a siRNA targeting the 3 0 UTR of the endogenous BRCA1 mRNA. Second, we expressed I-SceI to generate a double-strand break in the broken GFP reporter. Third, after allowing sufficient time for double-strand DNA break repair, we sorted cells into GFP þ and GFP À populations. We PCR amplified and sequenced the BRCA1 variants in each sorted population and counted DNA reads for each variant. We calculated a score for each variant by taking the ratio of its frequency in GFP þ cells to its frequency in GFP À cells and normalized to the equivalently calculated ratio for the WT transgene.
Scores from this pilot assay were largely consistent with published results for these 15 variants ( Figures 1C and  1D) ; the sole exception was the BRCA1 p.His41Arg variant, which demonstrated an intermediate level of activity in the multiplex assay but was defective in the singleton assay.
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Of note, independent data based on saturation genome editing (see Findlay et al.; 23 discussed further below) clearly support the classification of p.His41Arg as conferring loss of function, i.e., the result of the singleton assay. Because this was a single experiment, we interpreted this false negative (i.e., the inappropriate classification of p.His41Arg as intermediate rather than loss of function) as indicative of the need to perform replicate assays. We settled on four replicates as a good balance between confidence in results and the expense and difficulty of the procedure. We proceeded to scale up the assay to analyze hundreds of variants per experiment by focusing on BRCA1 residues 2-192.
We created two individual pools of barcoded site-saturation mutagenesis libraries. 13, 24 Pool 1 contained variants in residues 2-96, and pool 2 contained variants in residues 97-192 (Table S4) . We integrated the plasmids in each pool into the HeLa-DR-FRT cell line. We then performed four replicates of the multiplex HDR reporter assay on each pool by using either a siRNA against endogenous BRCA1 mRNA or a control siRNA (Table S5 ). The barcodes were amplified and sequenced from genomes of the GFP þ and GFP À cell populations. The score for each variant was calculated as described above for the small-scale assay (Table S6) . Variant scores between replicates were well correlated for pool 1 but less so for pool 2, for which most variants scored close to ln(0), indicating little or no depletion ( Figure S2 )
Functional Classification of Variants
A characteristic of all sequencing count data, including from multiplex assays for variant effects, is that the variance of scores increases at low read counts as a result of error from Poisson-distributed shot noise and stochastic dropout of variants. 20 This effect is exacerbated in cases such as the HDR reporter assay, which, despite being the gold-standard assay for BRCA1 missense variants, has a bottleneck. Specifically, at most, only $10% of the cells become GFP þ ; this bottleneck limits the dynamic range of functional scores (Table S5) . Because the score depends on read counts, we cannot directly compare the scores of any two variants. Therefore, we chose to construct a binary classifier (''depleted'' versus ''not depleted'') by modeling the relationship between the read counts and scores (Material and Methods). With this model, we compared the significance of each variant's depletion in the BRCA1 siRNA experiments with that of variants in the control siRNA experiments at the same read count in the same experiment (Figure 2A , Figure S3 , Material and Methods, and Table S6 ). To remove as many variants that could be substantially affected by stochastic dropout as possible, we applied a The correlation between scores from the 16-plex experiment and scores from individual HDR reporter assays. 13 The number of times the WT sequence was counted in the GFP þ cells was set to 1.0, and the counts of the indicated variants were scored in relation to the WT. Spearman rho and p values are reported. Bars and points are colored according to ClinVar variant interpretation. stringent read-count filter to the GFP À population and removed variants below this threshold from further analysis ( Figure S3 and Material and Methods). For each experimental replicate, the number of variants above the read-count threshold in the GFP À population varied, as did the number of variants classified as depleted (i.e., nonfunctional variants; Table 1 ). The Venn diagrams shown in Figure 2B indicate the number of variants found to be depleted among the four replicate experiments for each pool of variants. In each set of replicate experiments, some variants were scored as depleted only once. Most of these singletons were depleted as a result of stochastic dropout, but some were nonsense variants that passed the read-count filter only in one replicate (Table S6 ). The variants found to be depleted in three or four replicates were enriched at residues with known pathogenic variants (203 enrichment, p < 2.0 3 10 À16 , Fisher's exact test). Pool 1 (amino acids 2-96) had the highest proportion of nonfunctional variants, which is expected because the structured RING domain is encoded almost entirely by the positions mutated in pool 1. Pool 2 (amino acids 97-192) had many fewer nonfunctional variants; these included missense variants at the two remaining positions of the RING domain (97 and 98), which were repeatedly depleted from the functional GFP þ population. Many more variants were not depleted in the GFP þ population in both pools, and those variants were also shared between replicates ( Figure S4 ).
Variant Effects Measured in This Multiplex HDR Assay Are Strongly Concordant with Singleton HDR Assays and ClinVar Interpretations
In total, we measured the functional effects of 1,056 BRCA1 missense variants and four nonsense variants that were above the read-count threshold in three or more replicates. The great majority of BRCA1 missense variants were functional for DNA repair-only 59 variants (5.6%) were depleted from the population in three or four replicates and therefore likely to be nonfunctional for DNA repair ( Figure 3A) . Among the variants successfully tested, results from singleton HDR reporter assays were available for 16 variants. 11, 13, 14 All ten that had been scored as functional in HDR were depleted in zero replicates in the multiplex assay, and all six that were nonfunctional in singleton assays were depleted in three or four replicates of the multiplex assay ( Figure 3B ). The number of times that variants were depleted from the functional population in the multiplex HDR reporter assay was strongly correlated with the results of other multiplex functional assays. For example, we previously used in vitro ubiquitin ligase and BARD1-binding yeast two-hybrid scores to predict HDR function for variants within the first 102 amino acids of BRCA1. 13 The 234 variants (boxplots) that overlap in the two assays, including the 25 variants (points) that are also in ClinVar, are highly concordant ( Figure 3C ). Variants that were never depleted in the multiplex HDR reporter assay correspond to those in the previous study with higher HDR predictions, whereas variants that were repeatedly depleted correspond to those in the previous study with lower HDR predictions. However, the phageand yeast-based functional assays misidentified the known pathogenic variant p.Leu22Ser as functional, whereas it was correctly found to be defective in both single 13 and multiplex HDR experiments in human cells. The number of replicates in which variants were depleted from the multiplex HDR reporter assay was also strongly consistent with functional scores from a multiplex BRCA1 functional assay that relies on the survival of a haploid cell line after saturation genome editing (SGE) of exons in BRCA1 23 ( Figure 3D ). To an extent, the exceptions are predictable. The SGE-based functional assay identifies variants that reduce splicing because the variants are edited into their native context in the genome, whereas such variants are false negatives in the HDR reporter assay in which the BRCA1 ORF is not spliced (Figure 3D ; red points represent variants with reduced RNA).
Like the multiplex HDR reporter assay, the SGE assay is highly accurate for identifying variants that are damaging for protein function. However, some variants (p.Val14Gly, p.Cys44Gly, p.Glu85Gly, p.Ala92Gly, and p.Ala92Thr) are found to be damaging to protein function by the SGE assay but not the multiplex HDR reporter assay. None of these five variants have data or interpretations of cancer risk in ClinVar. In previous work, we individually compared the effects of amino acid substitutions on BRCA1 function in HDR versus repair by single-strand annealing (SSA). 15 Although HDR and SSA are both related mechanisms for repairing DNA double-strand breaks dependent on BRCA1, we found different tolerances for 7 of the 35 variants tested when we compared the two assays in that study. Although all seven of these were functional in HDR, three were nonfunctional in SSA and four had significantly depleted partial function in SSA. 15 When comparing the two multiplex assays for HDR and SGE, finding five differences among 118 comparisons is a low percentage (4%) and could reflect appropriate biology of the two assays. This is especially true given that the biochemical mechanism affecting cell growth in the SGE assay is unknown.
Of the five differences in the comparison of highthroughput HDR and SGE assays, p.Cys44Gly could be a false negative of the multiplex HDR reporter assay given that all amino acid substitutions in the cysteine and histidine residues that bind zinc ions in the BRCA1 RING domain and have been tested to date in singleton functional assays are damaging, [11] [12] [13] although this specific p.Cys44Gly variant has not before been tested for HDR function. Alternatively, p.Cys44Gly and the other discordant variants could be slightly destabilized and rescued by the expression level in the HDR reporter assay, or these residues could be necessary for another BRCA1 function critical for cell survival in the SGE assay. Clinical interpretations for some of the BRCA1 variants that we functionally score here are reported in ClinVar (accessed May 2018). 20 Of the 1,056 variants scored here, five were classified as benign or likely benign in ClinVar. All five were either never depleted or depleted in only one replicate in the multiplex HDR assay. In contrast, we tested eight BRCA1 variants that are established pathogenic variants in ClinVar. Of these, seven were depleted in three or four replicates in the multiplex HDR assay. The eighth pathogenic variant, p.Arg71Gly, had WT-like DNA repair activity in our data, a result consistent with previous HDR reporter assays. 15 p.Arg71Gly causes a defect in RNA splicing, 19 which as discussed above we do not expect to be detectable in our assay ( Figure 3E ). In summary, we observed strong concordance between variants depleted in zero or one replicates in our assay and benign status in ClinVar or WT-like function in other assays, as well as between variants depleted in three or four replicates in our assay and pathogenic status in ClinVar or loss of function in other assays. We therefore conclude that the number of replicates in which a variant is found depleted is a reasonable proxy for its functionality and term these depletion scores (range 0-4; Table S7 ).
Depletion Scores Identify Damaging BRCA1 Variants
Depletion scores for all variants passing the read-count threshold in at least three replicates are shown in the form of a sequence-function map in Figure 4A . 100% of the damaging amino acid substitutions (dark red) were observed in the first 98 amino acids, which comprise the RING domain, whereas residues 99-192 strongly tended to tolerate amino acid substitutions. Nonsense variants, indicated by the asterisk on the bottom row, were nonfunctional. The distribution of variants indicates that the degenerate positions in the mutagenic oligonucleotides used to make the site-saturation mutagenesis libraries contained a much higher fraction of guanines than the 1:1:1:1 ratio of the four nucleotides specified for the synthesis (see Material and Methods). Thus, codons containing guanine in the first or second position (particularly glycine, arginine, alanine, and valine) are the most highly represented. Given that the highest representation of substitutions was to glycine, we mapped the number of times each substitution to glycine was found depleted in replicate experiments to the solution structure of the BRCA1 and BARD1 RING domain dimer 25 ( Figure 4B ).
Amino acids positions that were the most intolerant to substitution were buried in either the interior of the fourhelix bundle, which acts as the BARD1 interface, or in the loops that coordinate zinc ions. We examined the depletion scores of 63 BRCA1 variants that are ambiguously classified in ClinVar (VUS or conflicting reports of pathogenicity) to predict their functional impact. Of 56 variants tested in the multiplex HDR reporter assay and classified as VUSs in ClinVar, two (p.Val11Gly and p.Ile68Arg) had a depletion score of 3 or 4 and are thus likely to be nonfunctional for HDR. Of eight variants that have conflicting interpretations of pathogenicity in ClinVar, three (p.Thr37Arg, p.His41Leu, and p.Cys47Gly) were nonfunctional in the DNA repair assay ( Figure 3E ). These seven variants, all ambiguous in ClinVar and nonfunctional in our assay, are at positions that coordinate zinc ions (p.Cys47Gly and p.His41Leu) or positions within the zinc-finger loops (p.Thr37Arg and p.Ile68Arg) or have side chains in the interior of the four-helix bundle (p.Val11Gly). Most known pathogenic missense variants map to these same structural features. Table S7 .
The remaining 58 variants that are ambiguously classified in ClinVar (VUS or conflicting reports of pathogenicity) have a low depletion score in our assay. Of these, 47 lie outside of the RING domain, where we did not identify any damaging amino acid substitutions. The 11 variants found within the structured RING include p.Gln81Glu, p.Ile90Val, and p.Ile90Thr, whose side chain points out of the four-helix bundle where amino acid changes are tolerated ( Figure 4B ). p.Thr77Met and p.Thr97Arg are substitutions to the amino acids that abut the helices and might not affect BARD1 binding; however, other changes at Thr97 are not tolerated, and VUS p.Thr97Ala has an ambiguous depletion score of two ( Figure 4A ). p.Ile42Leu and p.Ile68Val are in RING loops but are conservative changes and therefore might be tolerated; p.Glu29Gly, p.Glu33Ala, p.Gly57Arg, and p.Pro58Ala are also in the loops, but their side chains point away from the interior of the structure, which could be why they are tolerated. In studies of ubiquitin ligase activity, substitutions at Glu29 are damaging to ubiquitin ligase function 13 but not to HDR. This finding adds to the growing evidence that ligase activity is not required for BRCA1's HDR function.
26,27
Discussion
We developed a multiplex reporter assay to measure the effect of hundreds of amino acid substitutions in BRCA1 on HDR, the molecular function most closely associated with its role in tumor suppression. We reproducibly measured 1,056 of the possible 3,820 amino acid or nonsense substitutions (191 codons 3 20 amino acid or stop codon changes). Although these 1,056 constitute only 28% of all possible substitutions, to date, our assay is the highest-throughput assay that specifically analyzes the DNA repair function of BRCA1. Of the 12 variants known to be benign or pathogenic and assayed here, we classified them with 87.5% sensitivity and 100% specificity. 3 The assay was only 87.5% sensitive because it misclassified p.Arg71Gly, a cancer-associated variant that is pathogenic because of its impact on splicing, a feature not tested in the DNA repair assay. Coverage of more variants of known effect in future experiments will be required for more thoroughly validating this assay. In this multiplex HDR reporter assay, we used a cell line (HeLa) that was not derived from breast or ovarian tissue. The requirement for a high transfection efficiency restricted us to only a few choices of human cell lines. The function of BRCA1 in HDR is considered ubiquitous for all human cell types. Although the use of HeLa cells for HDR reporter assays produced results that accurately predict hereditary breast and ovarian cancer risk, this assay does not address the breast and ovarian specificity of loss of BRCA1 activity.
The nonuniform coverage of amino acid substitutions in our variant libraries was a technical challenge. Two features of the protocol employed here to make variant libraries 24 contributed to this nonuniformity. First, we performed inverse PCRs individually for each amino acid position by using individually synthesized oligonucleotides. Therefore, failed reactions and uneven mixing of the PCR products caused loss of all or most substitutions at some positions ( Figure 4A ). Second, a strong guanine bias at each degenerate nucleotide position during oligonucleotide synthesis led to a bias in the encoded amino acids ( Figure 4A ). We anticipate that if the distribution of variants in the library were more uniform, we would be able to query more variants per experiment (up to a theoretical maximum of $4,000 variants per experiment under ideal conditions) at our current number of sorted cells. Alternative approaches using array-derived oligonucleotides could create more uniformly distributed variant libraries. 28, 29 It might also be useful to limit the number of amino acid changes to those accessible by single-nucleotide changes because these are the missense variants relevant to human disease. However, this limitation would also reduce the information content of the multiplex experiments.
In addition to improving library uniformity, restricting the number of barcoded variants in each multiplex HDR reporter experiment should result in more variants that pass the read-count filter. For example, a higher percentage of variants passed the read-count threshold in pool 2 (50% on average) than in pool 1 (29%). The variant libraries for pools 1 and 2 contained similar numbers of barcoded variants. However, more variants were damaging to BRCA1 HDR function in pool 1, and thus only $7% of the ) is arranged along the x axis, and the position of the RING domain is diagrammed above. The amino acid substitutions, grouped by side-chain properties, are on the y axis, and nonsense codons are indicated by asterisks. The depletion scores range from never depleted or likely functional (white) to likely nonfunctional (dark red). Black ovals demarcate the WT residue, and gray indicates missing data. (B) The depletion score for amino acid substitutions to glycine are mapped to the solution structure of the BRCA1 1-102 and BARD1 26-125 dimer (PDB: 1JM7). 25 The color scale is the same as in (A), and spheres are shown for side chains at amino acid positions with a depletion score of 3 or 4. cells in this pool converted to being GFP þ after the doublestrand break, further limiting the dynamic range of pool 1 experiments. In summary, we describe the development of a multiplex assay for measuring the effects of amino acid substitutions on a protein's function in double-strand DNA break repair in human cells. We analyzed 1,056 amino acid substitutions of BRCA1 residues 2-192 and found that this approach yielded results comparable to those of lowthroughput HDR analysis of single variants and other functional assays. More importantly, our results are concordant with BRCA1 variants known to predispose to cancer and with BRCA1 variants previously identified to damage protein function. This assay can be repurposed to measure the effect of variants in other HDR pathway proteins that are also hereditary breast and ovarian cancer tumor suppressors, such as BRCA2 [30] [31] [32] and BARD1. 33, 34 As genetic testing for cancer risk becomes more common and additional genes are added to testing panels, the number of rare missense variants that inevitably become VUSs will continue to increase. We anticipate that multiplex functional assays can be used to functionally characterize such variants at scale, even before the variants are observed in results from genetic testing.
Accession Numbers
The accession number for the raw data reported in this article is GEO: GSE116427.
Supplemental Data
Supplemental Data include four figures, seven tables, and a test for variant depletion (provided in two file formats) and can be found with this article online at https://doi.org/10.1016/j.ajhg. 2018.07.016.
